Nanosonics Limited (ASX:NAN)
Australia · Delayed Price · Currency is AUD | Market Cap | 863.85M -29.8% |
| Revenue (ttm) | 203.89M +2.7% |
| Net Income | 17.84M -13.7% |
| EPS | 0.06 -13.8% |
| Shares Out | 298.91M |
| PE Ratio | 50.09 |
| Forward PE | 75.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,121,215 |
| Open | 2.920 |
| Previous Close | 2.890 |
| Day's Range | 2.885 - 2.950 |
| 52-Week Range | 2.640 - 4.760 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 3.85 (+33.22%) |
| Earnings Date | Aug 25, 2026 |
About Nanosonics
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In ... [Read more]
Financial Performance
In fiscal year 2026, Nanosonics's revenue was 203.89 million, an increase of 2.65% compared to the previous year's 198.63 million. Earnings were 17.84 million, a decrease of -13.74%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NAN stock is "Buy." The 12-month stock price target is $3.85, which is an increase of 33.22% from the latest price.
News
Nanosonics upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Nanosonics (NNCSF) to Outperform from Sector Perform with a price target of A$3.75, up from A$3. The firm says an overly bearish scenario is priced into the…
Nanosonics Earnings Call Transcript: H2 2026
FY 2026 saw 6% constant currency revenue growth and 21% EBIT growth, driven by record trophon placements and upgrades, disciplined cost control, and strong North American performance. CORIS is set for commercial launch in FY 2027, with significant investment and initial revenues expected in the low single-digit millions.
Nanosonics Annual report: H2 2026
Nanosonics has published its H2 2026 annual report on August 24, 2026.
Nanosonics Earnings release: H2 2026
Nanosonics released its H2 2026 earnings on August 24, 2026, summarizing the period's financial results.
Nanosonics Slides: H2 2026
Nanosonics has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 24, 2026.
Nanosonics Earnings Call Transcript: H1 2026
Revenue grew 9% year-over-year to AUD 102 million, with strong recurring revenue and operating margin expansion. Guidance for 8%-12% revenue growth is reaffirmed, supported by upgrades, new product launches, and disciplined cost management.
Nanosonics Quarterly report: H1 2026
Nanosonics has published its H1 2026 quarterly earnings report on February 23, 2026.
Nanosonics Slides: H1 2026
Nanosonics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 23, 2026.
Nanosonics Earnings release: H1 2026
Nanosonics released its H1 2026 earnings on February 23, 2026, summarizing the period's financial results.
Nanosonics upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Nanosonics (NNCSF) to Sector Perform from Underperform with an unchanged price target of A$4. The firm views the shares as fairly valued now that earnings estimates have…
Nanosonics Transcript: AGM 2025
The meeting highlighted strong financial growth, major product launches (trophon3 and CORIS), and a new share buyback. All board and remuneration resolutions passed with high support. Strategic focus remains on innovation, sustainability, and global expansion, with no dividend declared due to low franking credits.
Nanosonics Slides: FY 2025
Nanosonics has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 4, 2025.
Nanosonics downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital downgraded Nanosonics (NNCSF) to Underperform from Sector Perform with a price target of A$4, down from A$4.50. The company’s fiscal 2026 outlook fell significantly below estimates due to…
Nanosonics Earnings Call Transcript: H2 2025
Revenue grew 17% to AUD 198.6 million, with recurring revenue up 20% and profit before tax up 72%. FY 2026 guidance anticipates 8–12% revenue growth, gross margin of 75–77%, and continued investment in innovation, with minimal CORIS revenue expected.
Nanosonics Slides: H2 2025
Nanosonics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.
Nanosonics Earnings release: H2 2025
Nanosonics released its H2 2025 earnings on August 25, 2025, summarizing the period's financial results.
Nanosonics Annual report: H2 2025
Nanosonics has published its H2 2025 annual report on August 25, 2025.
Nanosonics upgraded to Buy from Hold at Canaccord
Canaccord analyst Elyse Shapiro upgraded Nanosonics (NNCSF) to Buy from Hold with a price target of A$4.74, up from A$4.47. FDA De Novo approval for the company’s Coris device for…
Nanosonics Earnings Call Transcript: H1 2025
Revenue rose 18% year-over-year to AUD 93.6 million, with strong growth in North America and Europe. Full-year revenue guidance was raised to 11%-14%, gross margin improved to 78.5%, and net profit increased 58%. Cash balance stands at AUD 144.5 million, with no debt.
Nanosonics Quarterly report: H1 2025
Nanosonics has published its H1 2025 quarterly earnings report on February 19, 2025.
Nanosonics Slides: H1 2025
Nanosonics has posted slides in relation to its H1 2025 quarterly earnings report, which was published on February 19, 2025.
Nanosonics Earnings release: H1 2025
Nanosonics released its H1 2025 earnings on February 19, 2025, summarizing the period's financial results.
Nanosonics Transcript: AGM 2024
The meeting reviewed a return to growth in FY 2024, with strong H2 performance, robust margins, and ongoing investment in R&D and sustainability. Strategic focus remains on expanding the trophon base, launching CORIS pending FDA approval, and strengthening governance and diversity. Shareholders discussed regulatory, competitive, and operational risks.
Nanosonics Slides: FY 2024
Nanosonics has posted slides in relation to its FY 2024 quarterly earnings report, which was published on November 11, 2024.
Nanosonics Earnings Call Transcript: H2 2024
Second half FY24 saw a strong revenue rebound, driven by capital unit sales and recurring revenue growth. FY25 guidance targets 8%-12% revenue growth, margin recovery, and continued investment in R&D and M&A, with hospital budget constraints easing but still present.